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The modern era of chemotherapy began when patients were treated
with the war gas sulfur mustard in 1931, first topically and then by
direct intratumoural injection. It was however felt to be too toxic for
continued human use. Nitrogen mustard, a second-generation
mustard, was subsequently tested by Alfred Gilman and his
colleagues, in mice and then in a patient with lymphosarcoma, in
1942. Gilman and Philips published a review of nitrogen mustard in
cancer therapeutics, in 1946 (Gilman and Philips, 1946). 
Since that time, conventional chemotherapy regimens have not
yielded any cures in patients with most of the common epithelial
neoplasms. More importantly, chemotherapy prolongs patient
survival in very few metastatic solid tumours. This situation
applies even to chemosensitive malignancies such as germ cell
tumours and lymphomas – a significant proportion of patients are
not cured by current drug regimens. Some of these patients relapse
after a considerable disease-free interval, suggesting that cures
may be achieved with an increase in drug dose. This idea underlies
the use of high dose chemotherapy with peripheral or bone marrow
stem cell rescue (HDT). HDT has led to cures of some haemato-
logical malignancies such as acute and chronic myelogenous
leukemia and high-grade lymphoma (O’Donnell et al, 1987; Philip
et al, 1987; Goldman, 1994). However, in solid tumors, such as
breast cancer (Eddy, 1992), testicular cancer (Nichols et al, 1992),
small cell lung cancer (Humblet et al, 1997), ovarian cancer (Extra
et al, 1992) and sarcoma (Samuels et al, 1989), HDT has had only
a minimal impact on survival (Savarese et al, 1997). The disap-
pointing results of HDT in solid tumours have been attributed to
numerous factors (Savarese et al, 1997). One of the fundamental
reasons for the negative results may be faulty pharmacological
assumptions. Clinical trials evaluating HDT for solid tumours have
been based on the principle that anticancer agents exhibit a linear
relationship between drug doses and tumour cell kill.
Consequently, if toxicities associated with high doses of
chemotherapy agents (up to 5-fold increased doses) could be
ameliorated, then cure for solid tumours would be possible.
However, the experimental evidence supporting this theory has not
been rigorously reviewed. In this paper, we examine the available
preclinical data to evaluate the existence of steep dose response
relationships in tumour cell kill for the chemotherapy agents
employed in HDT regimens. 
DOSE-RESPONSE RELATIONSHIPS IN CANCER
CHEMOTHERAPY
In cancer chemotherapy, a ‘sleep’ dose-response relationship
refers to a linear relationship between drug doses and fractional
cell kill for approximately 5 logs of tumour cells (Skipper et al,
1970; Jusko, 1987). The steepness of the dose-response curve
implies that a disproportionately high number of cancer cells are
killed when drug doses are minimally increased. This is in contrast
to most other classes of therapeutic agents, which exhibit a
sigmoidal dose-response relationship, with a linear relationship
between dose and response over a relatively narrow range of drug
doses. The plateau in this traditional curve suggests that after a
certain threshold dose, further increments do not lead to an
increased response (Figure 1). The concept of a steep dose
response relationship for anticancer drugs dates back to the 1960s
when Skipper et al (1964) predicted a log cell kill model for anti-
neoplastic drugs. In this model, the relationship between tumour
cell kill and drug dose was exponential, with the number of cells
killed by a given dose of drug being proportional to both the dose
of the drug and the number of cells exposed to the drug.
This model was based on observations in L1210 mouse
leukemia cells, which grew exponentially until they reached a
lethal tumour volume of 109 cells (1 cm3). Ninety-nine percent of
the leukemic cells divided at a constant rate. As a result, the
doubling time was always constant. In these cells, an effective
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chemotherapy regimen killed a constant fraction of exponentially
growing tumour cells, regardless of the initial tumour size. If a
given dose of a drug reduced 106 cells to 105 cells, the same
therapy applied against 104 cells would result in 103 surviving
cells. These two cytoreductions are both examples of ‘one-log’
kill, resulting in a 90% decrease in cell number. 
Goldin et al (1956) had also demonstrated that for many drugs,
the log-kill increased with increasing dose. In later studies by Frei
and Canellos (1980), a log-linear relationship between drug dose
and tumour cytoreduction was demonstrated in the AKR murine
lymphoma as well as L1210 cells. Frei et al (1988) subsequently
demonstrated a steep dose-response relationship in the MCF-7
human breast carcinoma cell line with the alkylating agents
BCNU, melphalan, and nitrogen mustard. These experiments
demonstrated that for many drugs, the log-kill increased with
increasing dose. Moreover, if two or more sensitive chemotherapy
drugs were combined, the log-kill would be multiplicative. This
implied that if drug A kills 90% of the cells and a given dose of
drug B kills 90%, drug A given with drug B should kill 90% of the
10% of cells left, resulting in a 99% cell kill. In this model,
tumours less than 106 cells should theoretically be eradicated by
six cycles of a three-chemotherapy regimen. 
These principles provided a rationale for adjuvant chemo-
therapy following removal of all clinically detectable tumour,
when the remaining tumour burden could be only 104 to 106 cells.
However, as has become evident from adjuvant studies in different
epithelial tumours, the vast majority of patients are not cured.
These findings have been explained by the presence of drug resis-
tant clones among the tumour cells. To achieve cure, therefore,
intrinsic and acquired drug resistance of tumour cells have to be
circumvented. HDT has been one approach in the attempt to over-
come drug resistance. 
DOSE INTENSITY (DI) 
With the acceptance of a ‘steep’ dose response curve of
chemotherapy agents for solid tumours, increased interest in deliv-
ering maximum tolerated drug doses as a strategy for overcoming
resistance to chemotherapy emerged. Levin and Hryniuk (1987)
introduced the concept of dose intensity, defined as the milligrams
per square metre of delivered drug per week of therapy. In a retro-
spective study, these workers demonstrated that dose intensity was
an independently significant correlate of relapse-free survival in
women with node-positive breast cancer (Hryniuk and Lavine,
1986). In this study, there was a linear relationship between the
projected increased dose intensity and improved 3-year relapse-
free survival (P < 0.00001). Similar results were reported in
another retrospective study by Levin and Hryniuk (1987) showing
improved median survival time with increased dose intensity in
ovarian cancer. These studies by Hryniuk and Levine triggered an
interest in the investigation of dose intensity in randomized
prospective controlled studies, in a wide variety of neoplasms.
These studies have demonstrated that dose intense chemotherapy
improves the outcome of patients with acute myelogenous
leukemia, multiple myeloma, and relapsed non-Hodgkin’s
lymphoma (Savarese et al, 1997). However, in solid tumours, dose
intense chemotherapy has yielded conflicting results (Savarese 
et al, 1997). A majority of studies have shown a higher response
rate for the dose intense arm versus the conventional arm, but in
the NSABP B-22 study (Fisher et al, 1997), a total of 2305 women
with node-positive breast cancer were randomized to one of three
treatment arms involving dose-escalated or dose-intensified
cyclophosphamide plus adriamycin. Group 1 was defined as the
standard arm (A = 60 mg/m2, C = 600 mg/m2 × 4 cycles); group 2
as the intensified arm (A = 60 mg/m2 × 4 cycles, C = 1220 mg/m2
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Figure 1 Theoretical dose-response curves for anticancer agents and conventional pharmacologic agents. Graph A shows a linear dose-response curve
demonstrating a decreased survival fraction as the drug dose increases, over a wide range of doses. Line c has a steeper slope (k) compared to line d slope (h).
Both achieve the same fraction of cell kill, but at different doses. For clinical purposes, if drug d has a favourable therapeutic index, its clinical antitumour activity
should not be different from drug c. Thus the linearity of the dose response curve over a broad achievable and tolerable dose-range is much more important
than the steepness of the curve. Graph B demonstrates a dose-response curve with a plateau as drug doses are increased. Graph A represents the accepted
nature of the dose-response curve for cytotoxic agents. Graph B represents the dose-response curve for most other pharmacologic agents486 LF Porrata and AA Adjei 
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× the first 2 cycles); and group 3 as the intensified and increased
total dose arm (A = 60 mg/m2, C = 1200 mg/m2 × 4 cycles).
Through 5 years of follow-up, there were no statistically signifi-
cant differences in disease-free survival (DFS) or overall survival
(OS) among the different groups. One explanation for the negative
results in B-22 was that the doses of cyclophosphamide were too
low to reveal a significant difference. To evaluate that possibility,
the NSABP conducted study B-25, in which the highest dose in B-
22 was used as the ‘baseline’ and proceeded to further escalate
cyclophosphamide, again testing both cumulative dose and dose
intensity (Fisher et al, 1999). All patients received growth factors.
There was no improvement in DFS or OS among the three arms of
the study. Several factors may explain the lack of a survival differ-
ence between dose intense regimens and conventional therapy.
Tumour cell heterogeneity may affect response to dose intense
regimens. Muss et al (1994) showed that dose intense therapy
improved outcome among the patients in whom the tumour
markedly over-expressed the c-erb2 (HER2) oncogene. Apart from
molecular characteristics, tumour factors such as tumour cell
kinetics, tumour size, and duration of tumour growth, as well as
drug features such as dose, schedule and delivery are all likely to
contribute to varying extent to determine the outcome of a partic-
ular treatment. Another possible explanation for the lack of
improved survival by dose intense therapy is the concept of a
threshold dose. In a study reported by Wood et al (1994), 1572
patients were divided into three groups using different doses of
CAF (cyclophosphamide, adriamycin, and fluorouracil). After a
median of 3.4 years of follow-up, the patients treated with high or
moderate dose intensity had significant longer DFS (P < 0.001)
and OS (P = 0.004) than those treated with a low dose intensity.
However, when comparing the DFS and OS between the high and
moderate dose intensity groups there was no significant difference
(P = 0.28 and P = 0.21, respectively). These results suggest that
lower threshold doses of therapy are associated with inferior
results and that higher doses than the threshold dose of therapy do
not affect outcome. Unfortunately, for most tumours, the threshold
dose of antineoplastic agents is unknown. It is likely that the resis-
tance mechanisms operating in solid tumours in the clinical setting
cannot be totally overcome by augmenting the dose of currently
available drugs. However, it can be argued that HDT may over-
come resistance but simply doubling the dose intensity, as was
done in most of these studies (Levin et al, 1993), is not enough. 
PRECLINICAL EVIDENCE FOR STEEP DOSE-
RESPONSE RELATIONSHIPS IN SOLID
TUMOURS 
Chemotherapy agents which are commonly used as conditioning
agents for HDT, are shown in Table 1. The available data from
preclinical studies of dose-response relationships of these agents in
solid tumour models, have been summarized in Tables 2, 3, and 4.
No studies could be found testing the existence of a steep dose-
response relationship for a majority of the chemotherapy agents,
including busulfan, carboplatin, carmustine, chlorambucil, de-
carbazine, epirubicin, hydroxyurea, and ifosfamide. Preclinical
studies have failed to show a log-linear dose-response relationship
over a broad range of doses in solid tumours for mitoxantrone (Von
Hoff et al, 1986), paclitaxel (Liebmann et al, 1993), topotecan 
(Ma et al, 1998), and vinblastine (Von Hoff et al, 1986). The dose
response curve for these agents is curvilinear. An initial propor-
tional tumour cell kill with dose increments, is followed by a
plateau, as doses are further increased. 
Paclitaxel 
Dose-response relationships for paclitaxel have been evaluated in
vitro, utilizing human breast, ovary, non-small cell lung and astro-
cytoma cell lines. (Liebmann et al, 1993). In the MCF-7 breast
cancer cell line, 5 µ M of paclitaxel produced a 0.5 log cell kill,
Table 1 Conditioning agents used in HDT for solid tumours 
BCNU Epirubicin Mitoxantrone 
Busulfan Etoposide Paclitaxel 
Carboplatin Hydroxyurea Teniposide 
Chlorambucil Ifosfamide Thiotepa 
Cisplatin Lomustine Topotecan 
Cyclophosphamide Melphalan Vinblastine 
Dacarbazine Methchlorethamine Vincristine 
Doxorubicin Mitomycin C 
Table 2 HDT conditioning agents demonstrating a log-linear dose-response 
Drug Cell line Linearity of response 
BCNU Breast MCF-7 (H) 5-logs 
Melphalan Breast MCF-7 (H) 5-logs 
Fibrosarcoma FsaII (M) 5-logs 
Head & Neck (H) 5-logs 
Nitrogen mustard Breast MCF-7 (H) 5-logs 
Cyclophosphamide + Thiotepa Breast MCF-7 (H) 5-logs 
H = human cell line; M = murine cell line. 
Table 3 HDT conditioning agents demonstrating a narrow log-linear-dose-
response 
Drug Cell line Linearity of response 
Cisplatin SCLC (H) 2-logs 
Testicular SuSa (H) 2-logs 
Fibrosarcoma FsaII (M) 2-logs 
Lung V79-171B (M) 2-logs 
Cyclophosphamide Breast MCF-7 (H) 2-logs 
Fibrosarcoma FsaII (M) 2-logs 
Doxorubicin Testicular SuSa (H) 2-logs 
Mitoxantrone Breast (H) 2-logs 
Ovarian (H) 1-log 
Paclitaxel Astrocytoma U-373 (H) 2-logs 
Breast MCF-7 (H) 1-log 
Lung A-549 (H) 2-logs 
Ovarian OVG-1 (H) 2-logs 
Thiotepa Breast MCF-7 (H) 2-logs 
Topotecan Breast MCF-7 (H) 2-logs 
H = human cell line; M = murine cell line. 
Table 4 HDT conditioning agents with no reported preclinical studies 
Busulfan Ifosfamide 
Carboplatin Lomustine 
Chlorambucil Mitomycin-C 
Dacarbazine Teniposide 
Epirubicin Vincristine 
Hydroxyurea The pharmacologic basis of high dose chemotherapy 487
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while 10 µ M of drug produced a 1.5 log cell kill. However, this
magnitude of cell kill remained unchanged at higher paclitaxel
doses of up to 10 µ M (Liebmann et al, 1993). In OVG-1 ovarian,
A-549 lung, and U-373 astrocytoma cell lines, 5 µ M of paclitaxel
produced a 1-log cell kill. Doubling the paclitaxel dose to 10 µ M
led to a 2-log cell kill. Further increments in paclitaxel doses failed
to increase cell kill. These results indicate a steep dose-response
relationship over a narrow concentration range for paclitaxel. In
these systems, there is no incremental cell kill after a concentration
of 10 µ M. The clinical implication would be that increasing the
amount of administered drug above a dose that would achieve
intra-tumoural levels above 10 µ M would only increase drug toxi-
city with no improvement in efficacy. 
Similar results were found with cisplatin, cyclophosphamide,
doxorubicin and thiotepa. In all the available studies with 
these agents, dose-response evaluations were reported for 
only two-fold dose increments. It is unclear whether higher drug
doses were tested and found not to yield any further tumour cell
kill. 
Cisplatin 
A doubling of the proportion of tumour cells killed with a
doubling of the cisplatin dose was seen in a human small cell lung
cancer (von Hoff et al, 1986), and testicular cancer cell line
(Walker et al, 1987), as well as in the FsaII murine fibrosarcoma
(Frei et al, 1988) and V79-171B chinese hamster lung cancer cell
lines (Durland and Godie, 1987). Data for higher doses of cisplatin
were not provided in these reports. 
Cyclophosphamide 
In vitro data were found for cyclophosphamide only in the FsaII
murine fibrosarcoma (Frei et al 1988) cell line. Doubling the dose
of cyclophosphamide in this cell line led to a 2-fold increase in
tumour cell kill. Again, data for higher doses of cyclophosphamide
were not provided. 
Doxorubicin 
In a similar fashion to cyclophosphamide, doubling the dose of
doxorubicin from 1.25 to 2.5 ng/ml produced a 2-fold cell kill in
the SuSa human testicular cancer cell line (Walker et al, 1987).
Further dose increments were not reported. 
Thiotepa 
Increasing the dose of thiotepa from 175 µ M to 300 µ M led 
to a 2-fold increase in cell kill in MCF-7 cells (Teicher et al, 
1988). No further data was provided regarding further dose
increases. 
BCNU 
A clear illustration of a steep dose-response relationship over 4
logs of cell kill – a close approximation to the Skipper–Schabel
model, was obtained in MCF-7 cells treated with the alkylating
agent, BCNU. In this cell line, 100 µ M of BCNU produced a 2-log
cell kill. Doubling the BCNU dose to 200 µ M led to a 4-log cell
kill (Frei et al, 1988). From these in vitro studies, BCNU would be
a rational choice for HDT in breast cancer. 
Melphalan 
A doubling of the proportion of tumour cells killed with a
doubling of the melphalan dose was seen in head and neck cancer
(no cell line reported) (Von Hoff et al, 1988). In MCF-7 cells,
25 µ M of melphalan produced a 2-log cell kill. Doubling the
melphalan dose to 50 µ M produced a 4-log cell kill. 25 mg/kg of
melphalan produced a 2.5-log cell kill in FsaII murine fibrosar-
coma (Frei et al, 1988). Doubling the melphalan dose to 50 mg/kg
produced a 5-log cell kill. Melphalan would also be a rational
choice for HDT in breast cancer. 
Nitrogen mustard 
In MCF-7 cells (Frei et al, 1988), 10 µ M of nitrogen mustard
produced a 2.5-log cell kill, while 20 µ M produced a 5-log cell
kill. Nitrogen mustard would be another rational choice for HDT
for breast carcinoma. 
COMBINATION STUDIES 
In spite of the lack of preclinical evidence for steep dose-response
relationships for some alkylating agents, some workers demon-
strated that synergistic cytotoxicity of certain drug combinations
achieved, in effect, steep dose-response relationships in a variety
of solid tumours. Schabel et al (1978; 1984) demonstrated syner-
gistic cytotoxicity of cyclophosphamide/nitrosourea, cyclophos-
phamide/melphalan, and melphalan/nitrosourea combinations in a
variety of cultured and implanted murine tumors. Utilizing MCF-7
cells, Teicher et al (1988) demonstrated a steep dose-response rela-
tionship with thiotepa and cyclophosphamide. At a thiotepa dose
of 50 µ M and a cyclophosphamide dose of 50 µ M, a 2-log cell kill
was obtained. Increasing the cyclophosphamide dose to 100 µ M
and maintaining the thiotepa dose at 50 µ M produced a 4-log of
cell kill. 
CLINICAL RESULTS OF HDT IN SOLID
TUMOURS 
The in vitro and in vivo studies by Frei et al (1988) and Von Hoff
et al (1986) discussed above as well as the studies by Schabel et al
(1978; 1984) demonstrating therapeutic synergism of combined
alkylating agents laid down the ground work for numerous Phase
I/II studies to evaluate HDT in solid tumours. In these HDT trials,
drug escalation continues until non-haematological toxicity
becomes dose-limiting. Dose intensification ranged from 3-fold of
standard doses (cisplatin) to over 100-fold (dacarbazine). The
toxic death rates following treatment in these studies range from 0
to 14%. While these death rates may not be significantly higher
than those seen in some studies utilizing standard doses of
chemotherapy, the incidence of immediate and long-term
morbility has not been adequately addressed. 
In addition to breast, lung, ovarian, and testicular cancer, HDT
has also been evaluated for colon cancer, CNS malignancies, and
sarcomas. Results from these studies are sketchy and inconclusive.
From the few data available, the duration of response for these
tumors are 3–8 months for colon cancer, 3–10 months for CNS
malignancies, and 3–66 months for sarcomas. 
The clinical outcome of patients treated with HDT has been
comprehensively reviewed recently (Savarese et al, 1997). In addi-
tion, four large prospectively randomized studies of HDT in breast488 LF Porrata and AA Adjei 
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cancer were recently reported. One study was in metastatic breast
cancer and three were in high-risk breast cancer patients (10 or
more positive lymph nodes and no distant metastases). In the study
of HDT and conventional therapy for metastatic breast cancer,
there was no significant advantage of HDT over standard therapy
(Stadtmauer et al, 2000). The median survival was 24 months with
HDT and 26 months with conventional CMF. Three-year survival
was 32% with HDT and 38% with conventional CMF (P = 0.28).
Median time to progression was 9.6 months with HDT and 9
months with conventional CMF (P = 0.31). An intent to treat
analysis demonstrated no difference in overall survival between
the two groups (P = 0.52). The CALGB 9082 Study (Peters et al,
1999) for high-risk breast cancer patients, reported early results of
the first 341 patients randomized to HDT versus an intermediate-
dose regimen out of a total of 785 patients randomized in the study.
The 3-year event-free survival was 68% in HDT group versus 64%
in the intermediate dose group (P = 0.1). The Scandinavian Breast
Cancer Study Group 9401 for high-risk breast cancer patients
reported preliminary data of 525 women randomized to nine
courses of FEC (5-FU, Epirubicin, and cyclophosphamide) or
three courses of FEC followed by HDT (cyclophosphamide, 
6g / m 2; thiotepa, 0.5 g/m2; and carboplatin 0.8 g/m2) (The
Scandinavian Breast Cancer Study Group 9401, 1999). At a
median follow-up of 23.7 months, there was no difference in the
number of relapses or in overall survival. Bezwoda et al (1999)
reported the only randomized study showing a significant benefit
of HDT over conventional therapy in high-risk breast cancer
patients. However, this study has been discredited because of
suspected scientific misconduct. Overall, these randomized studies
suggest that HDT may not offer any additional survival benefit
compared to conventional therapy, for breast cancer. It should be
noted that the HDT regimens in these studies contained agents for
which we could find no proof of a steep dose-response relationship
over a wide concentration range in human tumours. These agents
are etoposide, mitoxantrone, carboplatin, and cisplatin. 
CONCLUSION 
This review identified preclinical data supporting HDT with BCNU,
melphalan, and nitrogen mustard in cultured human tumours and
xenografts. Synergism was also demonstrated for combinations of
cyclophosphamide and thiotepa with each other, and with the
nitroso-ureas, melphalan and nitrogen mustard. A study of Table 4
indicates that there is no experimental basis for the choice of the
majority of preparative regimens used in HDT for solid tumors. The
choice of agents has been based on toxicity patterns. This empiri-
cism may explain in part the lack of clinical success with HDT. 
While pre-clinical models do not accurately predict clinical
outcome, it may still be useful to employ such models to select agents
which possess a log-linear relationship between dose and tumour cell
kill over a wide range of achievable concentrations in the target
tumours. In addition, specific high dose combinations may have utility
in tumours with certain molecular characteristics such as HER2 over-
expression. Such an approach would eliminate one confounding factor
as clinical investigators try to understand the limitations of HDT.
Secondly, specific hypotheses could be rationally tested. 
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